GeneDx Holdings had its Relative Strength (RS) Rating upgraded from 90 to 95 Tuesday.
Looking For The Best Stocks To Buy And Watch? Start Here
IBD's unique RS Rating tracks technical performance by showing how a stock's price action over the last 52 weeks measures up against that of the other stocks in our database.
History shows that the best stocks often have an RS Rating of over 80 in the early stages of their moves.
The IBD 50 stock is not currently offering a proper buying opportunity. See if the stock goes on to build a promising consolidation that could launch a new move.
The company reported 0% EPS growth last quarter, while sales growth came in at 40%.
The company holds the No. 2 rank among its peers in the Medical-Services industry group. Hims & Hers Health is the top-ranked stock within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
Stocks With Rising Relative Strength Ratings
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
